_page-0001.jpg)
.png)
Frontotemporal dementia (FTD) is the second most common cause of early onset dementia and is clinically characterized by progressive behavioral change, executive dysfunctions, and language difficulties. Clinical features of FTD include changes of personality, restlessness, loss of inhibition, apathy, social withdrawal and impulsiveness. Most patients with FTD display socially inappropriate behaviors, compulsive-like acts, poor insight and psychiatric features including hallucinations and paranoid delusions. FTD has not any specific treatment yet. Treatments for control of behavioral symptoms constitute majority of treatment approaches. Slowing progression of the disease is aimed with neuroprotective treatments. The management of FTD, a disorder characterized by varied behavioral symptoms, primarily involves the use of psychoactive medications. Although there are no approved treatments for the disorder; selective serotonin receptor inhibitors such as sertraline, paroxetine, or şuoxetine can decrease disinhibition-impulsivity, repetitive behaviors, and eating disorders in FTD. Low doses of trazodone or an atypical antipsychotic such as aripiprazole can also help manage significantly disturbed or agitated behavior. Case reports and open-label studies reported that aripiprazole, risperidone and olanzapine exert positive effects to control behavioral symptoms of FTD. This is a case report of FTD in a 69-year-old man. His symptoms started 7 years ago and he has been using sertraline 100 mg/day, quetiapine 100 mg/day, donepezil hydrochloride 10 mg/day. His compulsive behaviors and paranoid delusions did not respond to this treatment. Aripiprazole was added on existing treatment and after 4 weeks his compulsive behaviors and psychiatric symptoms regressed. We reported a patient with behavioral and psychiatric symptoms successfully treated with aripiprazole.